Why Aren’t Routine PET Scans Used After DLBCL Remission?

It is completely normal to feel anxious—a feeling often called “scanxiety”—when you finish frontline treatment for Diffuse Large B-Cell Lymphoma (DLBCL) and realize your doctor is not scheduling routine PET scans to check for relapse. During treatment, intense monitoring provides a sense of security. However, once your end-of-treatment scan shows a complete metabolic response (meaning no abnormal lymphoma-related metabolic activity is seen, often graded as a 1 to 3 on the Deauville scale), major guidelines from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) recommend against routine scheduled PET scans for asymptomatic patients ^[1][2].

While it might feel like you are being monitored less closely, the medical evidence shows that scheduling routine surveillance PET scans has not been shown to improve overall survival compared to monitoring through clinical exams and symptom reporting ^[1][3]. Furthermore, routine scans carry distinct risks, including high rates of false alarms, a cascade of additional testing, and cumulative radiation exposure ^[1][4][5].

Why Routine Scans Can Cause Unnecessary Follow-Up

PET scans are highly sensitive tests that detect areas of the body using large amounts of glucose (sugar). While lymphoma cells consume a lot of glucose, so do many non-cancerous processes. Once your treatment is complete, a PET scan can “light up” in areas of harmless inflammation, recovering tissue fibrosis, mild infections, or even benign nodules ^[6][7][8].

Because a scan cannot easily distinguish between benign inflammation and returning lymphoma, these non-cancerous glowing spots lead to false positives. The rate of false alarms is significant when scanning patients who have no symptoms. In one study of patients who had abnormal findings on a routine surveillance PET scan, roughly 50% of those positive results were false alarms, not actual lymphoma ^[4]. Another study measuring scan specificity in a surveillance setting found a 44% false-positive rate among patients who had not relapsed ^[3].

When a surveillance scan shows an abnormality, it creates uncertainty. Your care team cannot simply ignore a glowing spot, which often triggers a stressful cascade of follow-up care. You may need repeat imaging, specialist consultations, or surgical biopsies to definitively rule out a relapse ^[6][7][4]. While these procedures are medically appropriate to investigate the scan results, they cause severe anxiety and physical tolls that could be avoided by not performing the low-value routine scan in the first place.

Cumulative Radiation Exposure

Another reason care teams avoid routine PET scans is to protect your long-term health. PET/CT scans expose the body to ionizing radiation. A single follow-up PET/CT scan delivers an effective radiation dose (estimated at around 16.9 mSv in one protocol, though the exact amount depends on your size and the specific scanner settings), and repeating this identically every few months adds up ^[9].

The cumulative radiation from repeated surveillance imaging introduces a small but modeled risk of developing secondary cancers later in life ^[5]. Balancing this risk is a core part of post-treatment care: if you have symptoms that suggest a relapse, the diagnostic benefit of a scan completely outweighs the small radiation risk, and you should never fear a scan your clinician recommends ^[1][10]. However, exposing you to radiation routinely when you have no symptoms offers very little benefit.

How Your Care Team Will Monitor You

Stopping routine PET scans does not mean stopping follow-up care. Guidelines emphasize symptom-directed monitoring, which is an active and highly effective way to watch for relapse ^[1][2].

Your personalized follow-up care will likely consist of:

• Physical examinations: Your doctor will regularly check your lymph nodes, spleen, and overall health at scheduled survivorship visits.
• Blood tests: Routine lab work often includes checking your lactate dehydrogenase (LDH), a non-specific marker of tissue damage. Keep in mind that LDH is not a perfect test for relapse—a normal result does not guarantee the cancer is gone, and an elevated result can be caused by many non-cancerous issues ^[11].
• Symptom reporting: You are the most important part of your surveillance plan. Most relapses are discovered because a patient notices physical changes, not because of a scheduled scan.

You should contact your care team promptly if you experience B symptoms (unexplained fevers, drenching night sweats, or unintended weight loss), new and persistent lumps, unusual localized pain, or neurological changes like new weakness or nerve pain ^[11]. If your symptoms or physical exams raise concern, your care team will evaluate you and may promptly order appropriate targeted imaging (such as a CT or PET scan) or a tissue biopsy to determine what is going on ^[1][10].